<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="106258">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721096</url>
  </required_header>
  <id_info>
    <org_study_id>12-398</org_study_id>
    <nct_id>NCT01721096</nct_id>
  </id_info>
  <brief_title>XIENCE PRIME Japan Post-Marketing Surveillance (PMS)</brief_title>
  <official_title>XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the PMS are to observe the frequency, type, and degree of device
      deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to
      collect information on evaluation of the efficacy and safety for reevaluation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of the PMS are to observe the frequency, type, and degree of device
      deficiency to assure the safety of the new medical device (XIENCE PRIME) as well as to
      collect information on evaluation of the efficacy and safety for reevaluation by
      Pharmaceuticals and Medical Devices Agency (PMDA).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Stent Thrombosis (ST)</measure>
    <time_frame>Time Frame: Acute (0-24 hours)</time_frame>
    <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subacute Stent Thrombosis (ST)</measure>
    <time_frame>Subacute (&gt;24 hours to 30 days)</time_frame>
    <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Late Stent Thrombosis (ST)</measure>
    <time_frame>Late (&gt;30 days to 1 year)</time_frame>
    <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Stent Thrombosis</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success Rate: Implant Success Rate by Device</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate: Procedural Success by Lesion</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success Rate: Implant Success by Patient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Target Lesion Failure</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Target Lesion Failure</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>8 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</measure>
    <time_frame>1 year post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Target Vessel Failure</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Target Vessel Failure</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Death or MI</measure>
    <time_frame>8 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Death or MI</measure>
    <time_frame>1 year post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death or MI</measure>
    <time_frame>8 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death or MI</measure>
    <time_frame>1 year post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death or Target Vessel MI</measure>
    <time_frame>8 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint of Cardiac Death or Target Vessel MI</measure>
    <time_frame>1 year post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (Non-TLR)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (Non-TLR)</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TLR or TVR Non-TLR)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TLR or TVR Non-TLR)</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target Vessel Revascularization (Non-TVR)</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Revascularization</measure>
    <time_frame>1 year post index procedure</time_frame>
    <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>8 months post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>1 year post index procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Baseline</time_frame>
    <description>The value calculated as 100 * (1 - minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>Post procedure</time_frame>
    <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Diameter Stenosis (%DS)</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Gain: In-stent, In-segment</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>The difference between post- and pre-procedural MLD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late Loss(LL): In-stent, In-segment, Proximal, and Distal</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Late loss is calculated as MLD post procedure - MLD at follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Net Gain: In-stent, In-segment</measure>
    <time_frame>8 months post index procedure</time_frame>
    <description>Late procedural outcome is influenced by both the acute gain provided by the intervention (pre to post) and the subsequent late loss that occurs after the intervention (post to follow-up).The net gain is thus the sum of the offsetting effects of acute gain and late loss (net gain = acute gain - late loss).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">536</enrollment>
  <condition>Angina</condition>
  <condition>Coronary Occlusion</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Coronary Artery Stenosis</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>XIENCE PRIME - Long Length (LL)</arm_group_label>
    <description>323 patients receiving LL stent in 28, 33, or 38 mm length</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XIENCE PRIME - Core Size</arm_group_label>
    <description>213 patients with 8, 12, 15, 18 or 23 mm stents</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME - Long Length (LL)</intervention_name>
    <description>Long Length</description>
    <arm_group_label>XIENCE PRIME - Long Length (LL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>XIENCE PRIME - Core Size</intervention_name>
    <description>Core Size</description>
    <arm_group_label>XIENCE PRIME - Core Size</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients in Japan, who are eligible to receive treatment for coronary arteries using
        the XIENCE PRIME Everolimus-Eluting Stent System are to be enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ischemic heart disease who are eligible for treatment with XIENCE PRIME
             Everolimus Eluting Stent

          -  Patient provides Informed Consent Form

        Exclusion Criteria:

          -  If it is known at the time of index procedure that the patient is not able to return
             for the 8-month follow-up visit for angiogram and for the 1-year clinical follow-up,
             then the patient should not be registered in the PMS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kozuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Teikyo University Hospital, Tokyo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abbott Vascular Japan Co., Ltd.</name>
      <address>
        <city>Tokyo</city>
        <zip>108-6304</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 26, 2016</lastchanged_date>
  <firstreceived_date>September 20, 2012</firstreceived_date>
  <firstreceived_results_date>July 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Angioplasty</keyword>
  <keyword>Drug eluting stents</keyword>
  <keyword>Stents</keyword>
  <keyword>Real world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Coronary Occlusion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Period:October 11, 2012 to June 30 2013; Number of Patients enrolled:536 from 25 sites (213 in the Core Size arm;323 in the Long Length arm).all the patients except those terminated the surveillance have completed their follow-up at 8 months,1,2 and 3 years.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>XIENCE PRIME - Long Length (LL)</title>
          <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
        </group>
        <group group_id="P2">
          <title>XIENCE PRIME - Core Size</title>
          <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Follow-up Completed at 8 Months</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="323"/>
                <participants group_id="P2" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Completed at 1 Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Completed at 2 Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="315"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Follow-up Completed at 3 Year</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="307"/>
                <participants group_id="P2" count="206"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="204"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>XIENCE PRIME - Long Length (LL)</title>
          <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
        </group>
        <group group_id="B2">
          <title>XIENCE PRIME - Core Size</title>
          <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="323"/>
            <count group_id="B2" value="213"/>
            <count group_id="B3" value="536"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.6" spread="10.7"/>
                    <measurement group_id="B2" value="69.1" spread="10.4"/>
                    <measurement group_id="B3" value="68.8" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="167"/>
                    <measurement group_id="B3" value="431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="323"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Stent Thrombosis (ST)</title>
        <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
        <time_frame>Time Frame: Acute (0-24 hours)</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Stent Thrombosis (ST)</title>
          <description>Stent thrombosis was defined by Academic Research Consortium (ARC) criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any Myocardial infarction (MI) related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Subacute Stent Thrombosis (ST)</title>
        <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
        <time_frame>Subacute (&gt;24 hours to 30 days)</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Subacute Stent Thrombosis (ST)</title>
          <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Late Stent Thrombosis (ST)</title>
        <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
        <time_frame>Late (&gt;30 days to 1 year)</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Late Stent Thrombosis (ST)</title>
          <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Definite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definite/Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Stent Thrombosis</title>
        <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
        <time_frame>1 year post index procedure</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Stent Thrombosis</title>
          <description>Stent thrombosis was defined by ARC criteria as definite (angiographic confirmation with at least one of the following: acute onset of ischemic symptoms at rest, new ischemic ECG changes that suggest acute ischemia or typical rise and fall of cardiac biomarkers OR pathological confirmation at autopsy or via examination of tissue retrieved following thrombectomy), probable (any unexplained death within the first 30 days or, regardless of the time after the index procedure, any MI related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any other obvious cause), and possible (any unexplained death from 30 days after intracoronary stenting until end of trial follow-up). Stent thrombosis was categorized as acute (0-24 hours post stent implantation), Subacute (&gt;24 hours to 30 days post stent implantation), late (&gt;30 days to 1 year post stent implantation), or very late (&gt;1 year post stent implantation).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: Implant Success Rate by Device</title>
        <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: Implant Success Rate by Device</title>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>XIENCE PRIME stents</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="522"/>
                <count group_id="O2" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.9" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: Procedural Success by Lesion</title>
        <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: Procedural Success by Lesion</title>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="402"/>
                <count group_id="O2" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Success Rate: Implant Success by Patient</title>
        <time_frame>Participants will be followed for the duration of hospital stay, an average of 5 days</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Success Rate: Implant Success by Patient</title>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Target Lesion Failure</title>
        <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Target Lesion Failure</title>
          <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Target Lesion Failure</title>
        <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Target Lesion Failure</title>
          <description>Target lesion failure includes cardiac death, Target vessel MI and ischemia driven TLR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of All Death/All MI/All Revascularization (DMR)</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
        <time_frame>8 months post index procedure</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Target Vessel Failure</title>
        <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
        <time_frame>1 year post index procedure</time_frame>
        <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Target Vessel Failure</title>
          <description>Target vessel failure includes cardiac death, MI and ischemia driven TLR; ischemia driven TVR, non TLR; ischemia driven TVR (TLR or TVR, non-TLR).</description>
          <population>The number of participants analyzed excludes subjects who were lost-to-follow-up.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
        <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death/All MI/CI-TLR (MACE)</title>
          <description>Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial-infarction, and clinically-indicated target lesion revascularization (CI-TLR).</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Death or MI</title>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Death or MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Death or MI</title>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Death or MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9"/>
                    <measurement group_id="O2" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death or MI</title>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death or MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death or MI</title>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death or MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death or Target Vessel MI</title>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death or Target Vessel MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint of Cardiac Death or Target Vessel MI</title>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint of Cardiac Death or Target Vessel MI</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death includes cardiac death, non-cardiac death and non-coronary death.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Myocardial Infarction</title>
        <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <description>The endpoint myocardial infarction includes ST-elevation MI, non ST-elevation MI, Q wave MI and non Q wave MI</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization</title>
        <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization</title>
          <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Lesion Revascularization</title>
        <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization</title>
          <description>Target lesion revascularization (TLR) includes ischemia driven TLR and non-ischemia driven TLR.
Target lesion revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (Non-TLR)</title>
        <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (Non-TLR)</title>
          <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (Non-TLR)</title>
        <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (Non-TLR)</title>
          <description>Target vessel revascularization (TVR) includes ischemia driven TVR, non-TLR and non- ischemia driven TVR, non-TLR</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TLR or TVR Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TLR or TVR Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Vessel Revascularization (TLR or TVR Non-TLR)</title>
        <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Target Vessel Revascularization (TLR or TVR Non-TLR)</title>
          <description>Target vessel revascularization (TLR or TVR, non-TLR) includes ischemia driven TVR (TLR or TVR non-TLR) or non-ischemia driven TVR (TLR or TVR non-TLR)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-target Vessel Revascularization (Non-TVR)</title>
        <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Non-target Vessel Revascularization (Non-TVR)</title>
          <description>Any revascularization in a vessel other than the target vessel is considered a non-target vessel revascularization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.5"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Revascularization</title>
        <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>All Revascularization</title>
          <description>All revascularization includes ischemia driven and non-ischemia driven revascularization.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding</title>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding</title>
        <time_frame>1 year post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1 - minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1 - minimum lumen diameter/reference vessel diameter) (MLD/RVD) using the mean values from two orthogonal views (when possible) by quantitative coronary angiography (QCA).</description>
          <units>percentage of DS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of lesion analyzed</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.96" spread="17.73"/>
                    <measurement group_id="O2" value="70.27" spread="15.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
        <time_frame>Post procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
          <units>percentage of DS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of lesion analyzed</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="375"/>
                <count group_id="O2" value="245"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.94" spread="11.76"/>
                    <measurement group_id="O2" value="23.58" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Diameter Stenosis (%DS)</title>
        <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
        <time_frame>8 months post index procedure</time_frame>
        <population>Number of participants analyzed includes the number available for QCA.</population>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Diameter Stenosis (%DS)</title>
          <description>The value calculated as 100 * (1 - MLD/RVD) using the mean values from two orthogonal views (when possible) by QCA.</description>
          <population>Number of participants analyzed includes the number available for QCA.</population>
          <units>percentage of DS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="236"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Number of lesion analyzed</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="275"/>
                <count group_id="O2" value="175"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.15" spread="15.52"/>
                    <measurement group_id="O2" value="25.12" spread="12.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Gain: In-stent, In-segment</title>
        <description>The difference between post- and pre-procedural MLD.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Gain: In-stent, In-segment</title>
          <description>The difference between post- and pre-procedural MLD.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.56"/>
                    <measurement group_id="O2" value="1.81" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.62"/>
                    <measurement group_id="O2" value="1.40" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Late Loss(LL): In-stent, In-segment, Proximal, and Distal</title>
        <description>Late loss is calculated as MLD post procedure  MLD at follow-up.</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Late Loss(LL): In-stent, In-segment, Proximal, and Distal</title>
          <description>Late loss is calculated as MLD post procedure  MLD at follow-up.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.41"/>
                    <measurement group_id="O2" value="0.15" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proximal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.44"/>
                    <measurement group_id="O2" value="0.08" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.36"/>
                    <measurement group_id="O2" value="0.03" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.51"/>
                    <measurement group_id="O2" value="0.06" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Net Gain: In-stent, In-segment</title>
        <description>Late procedural outcome is influenced by both the acute gain provided by the intervention (pre to post) and the subsequent late loss that occurs after the intervention (post to follow-up).The net gain is thus the sum of the offsetting effects of acute gain and late loss (net gain = acute gain  late loss).</description>
        <time_frame>8 months post index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>XIENCE PRIME - Long Length (LL)</title>
            <description>323 patients receiving LL stent in 28, 33, or 38 mm length
XIENCE PRIME - Long Length (LL): Long Length</description>
          </group>
          <group group_id="O2">
            <title>XIENCE PRIME - Core Size</title>
            <description>213 patients with 8, 12, 15, 18 or 23 mm stents
XIENCE PRIME - Core Size: Core Size</description>
          </group>
        </group_list>
        <measure>
          <title>Net Gain: In-stent, In-segment</title>
          <description>Late procedural outcome is influenced by both the acute gain provided by the intervention (pre to post) and the subsequent late loss that occurs after the intervention (post to follow-up).The net gain is thus the sum of the offsetting effects of acute gain and late loss (net gain = acute gain  late loss).</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="323"/>
                <count group_id="O2" value="213"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Lesions</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="377"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" spread="0.66"/>
                    <measurement group_id="O2" value="1.68" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Segment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.67"/>
                    <measurement group_id="O2" value="1.34" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>XIENCE PRIME - Long Length (LL)</title>
          <description>XIENCE PRIME - Long Length (LL): Long Length- 323 patients receiving LL stent in 28, 33, or 38 mm length.</description>
        </group>
        <group group_id="E2">
          <title>XIENCE PRIME - Core Size (CS)</title>
          <description>XIENCE PRIME - Core Size: Core Size- 213 patients with 8, 12, 15, 18 or 23 mm stents.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Myocardial ischemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Large intestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Outcome of Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Subdural hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Exercise test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Trophic disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Crystal arthropathic disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of renal pelvis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Subarachnoid hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Peripheral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="213"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Coronary restenosis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="323"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="213"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David R Rutledge</name_or_title>
      <organization>Abbott Vascular</organization>
      <phone>(408) 845-3820</phone>
      <email>david.rutledge@av.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
